Altera Expands 28 nm Portfolio by Launching Arria V GZ Variant

Altera Corporation today announced it has expanded its 28 nm portfolio with the introduction of the Arria® V GZ variant, incorporating the company's industry-leading transceiver technology and delivering an overall core performance boost of more than two speed grades, or 30 percent.

This latest variant from Altera is designed to meet the demand for more bandwidth in communications and broadcast applications. Arria V GZ FPGAs feature 36 backplane-capable transceivers that can operate at speeds up to 12.5 Gbps and enable of a variety of protocols. In addition, the variant features four separate DDR3 DIMM interfaces at 72 bits wide, operating at 1600 Mbps. The combination of transceivers, fabric performance and quantity of available off-chip memory interfaces in Arria V GZ is unique for midrange FPGAs.

"Customers face many challenges when designing high-performance systems, including the need to balance power and performance while increasing bandwidth to off-chip memory," said Patrick Dorsey, senior director of component product marketing at Altera Corporation. "The Arria V GZ variant provides both the high-speed serial transceivers and the external memory capability that designers need to build today's bandwidth-hungry data processing systems."

Additional features of Arria V GZ devices include:

  • First midrange FPGAs to feature hardened PCI Express® Gen3 protocol stacks
  • Soft intellectual property (IP)-based memory controllers allowing for maximum flexibility
  • Most digital signal processing (DSP) in a midrange FPGA for high integration
  • Industry-leading, anti-tamper features, including enhanced advanced encryption standard (AES) and easy-to-use on-board and off-board key programming

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.